CiteFacts · FDA Drug Shortages · FDA source
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection
Status
FDA currently lists this ingredient in shortage.
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Presentation | FDA availability field | FDA update |
|---|---|---|---|
| Fresenius Kabi USA, LLC | Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27) | Unavailable | 08/04/2026 |
| Fresenius Kabi USA, LLC | Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57) | Unavailable | 08/04/2026 |
| Fresenius Kabi USA, LLC | Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27) | Available | 08/04/2026 |
| Fresenius Kabi USA, LLC | Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57) | Available | 08/04/2026 |
| Hospira, Inc., a Pfizer Company | Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03) | Limited Availability | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01) | Unavailable | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01) | Limited Availability | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02) | Unavailable | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01) | Unavailable | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01) | Limited Availability | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03) | Available | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01) | Unavailable | 08/07/2026 |
| Hospira, Inc., a Pfizer Company | Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02) | Limited Availability | 08/07/2026 |
Source facts
Grouped generic ingredient: Epinephrine Bitartrate, Lidocaine Hydrochloride Injection · 22 package records · Latest FDA row update: 08/07/2026
Therapeutic categories: Anesthesia, Pediatric
Dosage forms: Injection
Routes: EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-08-22T15:54:11+00:00. Derived grouping is documented in this record's derivations.